立体定向消融放疗治疗转移性癌症寡进展性疾病的系统综述
该系统综述遵循PRISMA指南,检索Medline和Embase数据库,纳入33项全文研究,评估立体定向消融放疗(SABR)治疗寡进展性疾病的疗效。研究发现,在寡进展性前列腺癌、非小细胞肺癌和肾癌患者中,中位无进展生存期超过6个月。SABR似乎对寡进展性前列腺、肺和肾癌患者具有临床获益,但由于缺乏前瞻性数据,最佳管理仍有些不明确。
要点
- 系统综述纳入33项研究,评估SABR治疗寡进展性疾病的疗效。
- 寡进展性前列腺癌、非小细胞肺癌和肾癌患者的中位PFS超过6个月。
- SABR似乎对寡进展性前列腺、肺和肾癌患者有临床获益,但缺乏前瞻性数据,最佳管理仍不确定。
核心结论
- SABR似乎对寡进展性前列腺、肺和肾癌患者具有临床获益。
- 由于缺乏前瞻性数据,寡进展性疾病患者的最佳管理仍有些不确定。
- 随着进一步随机试验的发表,这一点有望在不久的将来变得更加明确。
研究设计与样本
- 系统综述遵循PRISMA指南,检索Medline和Embase数据库,检索词为「stereotactic radiotherapy」或「SABR」或「Stereotactic Ablative Body Radiotherapy」或「SBRT」或「SRT」与「oligoprogression」,检索时间分别为2022年5月、2023年6月和2024年2月。
- 排除标准包括:SABR用作根治性治疗、无法识别特定寡进展队列、会议摘要或招募患者少于10例的研究,以及仅治疗脑转移的研究。
- 纳入33项全文研究,包括单中心和多机构观察性研究、病例系列和II期试验。
主要发现
- 22项研究涉及特定肿瘤类型:12项泌尿系统癌症(9项前列腺癌,3项肾癌),6项非小细胞肺癌,2项结直肠癌,2项乳腺癌;11项研究涵盖多个肿瘤部位(5项涉及SABR至单一器官,6项涉及SABR至多器官)。
- 寡进展性前列腺癌、非小细胞肺癌和肾癌患者的中位PFS超过6个月。
局限性
- 由于缺乏前瞻性数据,寡进展性疾病患者的最佳管理仍有些不确定。
- 随着进一步随机试验的发表,这一点有望在不久的将来变得更加明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stereotactic Ablative Radiotherapy (SABR) for the treatment of oligometastatic disease can improve survival and delay the requirement for systemic therapy. The benefits of SABR in oligoprogressive disease are less well-defined. Here, we evaluate the available evidence investigating the efficacy of SABR in the treatment of oligoprogressive disease. METHODS: A systematic review was carried out following PRISMA guidelines. Medline and Embase databases were searched using the terms "stereotactic radiotherapy" OR "SABR" OR "Stereotactic Ablative Body Radiotherapy" OR "SBRT" OR "SRT" AND "oligoprogression" in May 2022, June 2023, and February 2024. Studies were excluded where: SABR was used as a radical treatment, a specific oligoprogressive cohort could not be identified, publication was as a conference abstract or where fewer than 10 patients were recruited. Studies treating only brain metastases were also excluded. The site of primary tumour, oligoprogressive sites, rates of overall survival (OS), progression free survival (PFS), local control (LC) and time to next systemic therapy were collected. RESULTS: Thirty-three full text studies were included. These consisted of single centre and multi-institutional observational studies, case series and phase II trials. Twenty-two studies were related to a specific tumour type: 12 urological cancer (9 prostate, 3 renal cancer), 6 non-small cell lung cancer, 2 colorectal cancer, 2 breast cancer and 11 were studies covering multiple tumour sites (5 studies involving SABR to a single organ and 6 studies involving SABR to multi-organ). Median PFS was >6 months in patients with oligoprogressive prostate, non-small cell lung cancer and renal cancer patients. CONCLUSIONS: SABR appears to have clinical benefit in oligoprogresssive prostate, lung, and renal patients. However, the optimal management of patients with oligoprogressive disease is still somewhat uncertain due to lack of prospective data. This will hopefully become clearer in the near future with the publication of further randomised trials.
引用
- Doyle E, Killean AJ, Harrow S, et al. Systematic review of the efficacy of stereotactic ablative radiotherapy for oligoprogressive disease in metastatic cancer. Radiother Oncol. 2024. PMID: 38648995. doi:10.1016/j.radonc.2024.110288
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。